Home › Compare › MEDXF vs MCD

MEDXF vs MCD: Dividend Comparison 2026

MEDXF yields 89.29% · MCD yields 2.34%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MEDXF wins by $2.41M in total portfolio value
10 years
MEDXF
MEDXF
● Live price
89.29%
Share price
$2.24
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.49M
Annual income
$776,963.67
Full MEDXF calculator →
MCD
McDonald's Corporation
● Live price
2.34%
Share price
$310.79
Annual div
$7.26
5Y div CAGR
42.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$77.7K
Annual income
$25,833.37
Full MCD calculator →

Portfolio growth — MEDXF vs MCD

📍 MEDXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMEDXFMCD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MEDXF + MCD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
MEDXF pays
MCD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MEDXF
Annual income on $10K today (after 15% tax)
$7,589.29/yr
After 10yr DRIP, annual income (after tax)
$660,419.12/yr
MCD
Annual income on $10K today (after 15% tax)
$198.56/yr
After 10yr DRIP, annual income (after tax)
$21,958.36/yr
At 15% tax rate, MEDXF beats the other by $638,460.76/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MEDXF + MCD for your $10,000?

MEDXF: 50%MCD: 50%
100% MCD50/50100% MEDXF
Portfolio after 10yr
$1.28M
Annual income
$401,398.52/yr
Blended yield
31.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MCD right now

MEDXF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
0.9
Piotroski
5/9
MCD
Analyst Ratings
37
Buy
23
Hold
1
Sell
Consensus: Buy
Price Target
$351.76
+13.2% upside vs current
Range: $320.00 — $385.00
Altman Z
4.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MEDXF buys
0
MCD buys
0
No recent congressional trades found for MEDXF or MCD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMEDXFMCD
Forward yield89.29% ✓2.34%
Annual dividend / share$2.00$7.26 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%42.3% ✓
Portfolio after 10y$2.49M$77.7K ✓
Annual income after 10y$776,963.67 ✓$25,833.37
Total dividends collected$2.19M$57.7K ✓
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusHoldBuy

Year-by-year: MEDXF vs MCD ($10,000, DRIP)

YearMEDXF PortfolioMEDXF Income/yrMCD PortfolioMCD Income/yrGap
1← crossover$19,629$8,928.57$10,812$332.41+$8.8K → MEDXF
2$37,382$16,378.98$11,819$488.02+$25.6K → MEDXF
3$69,150$29,152.23$13,111$724.37+$56.0K → MEDXF
4$124,390$50,399.46$14,832$1,091.05+$109.6K → MEDXF
5$217,827$84,729.38$17,219$1,675.85+$200.6K → MEDXF
6$371,743$138,667.67$20,688$2,641.85+$351.1K → MEDXF
7$618,933$221,167.77$25,990$4,309.70+$592.9K → MEDXF
8$1,006,401$344,142.93$34,590$7,351.77+$971.8K → MEDXF
9$1,599,826$522,977.14$49,535$13,285.25+$1.55M → MEDXF
10$2,488,777$776,963.67$77,746$25,833.37+$2.41M → MEDXF

MEDXF vs MCD: Complete Analysis 2026

MEDXF — Stock

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.

Full MEDXF Calculator →

MCD — Consumer Discretionary

McDonald's Corporation operates and franchises McDonald's restaurants in the United States and internationally. Its restaurants offer hamburgers and cheeseburgers, chicken sandwiches and nuggets, wraps, fries, salads, oatmeal, shakes, desserts, sundaes, soft serve cones, bakery items, soft drinks, coffee, and beverages and other beverages, as well as breakfast menu, including biscuit and bagel sandwiches, breakfast burritos, hotcakes, and other sandwiches. As of December 31, 2021, the company operated 40,031 restaurants. McDonald's Corporation was founded in 1940 and is headquartered in Chicago, Illinois.

Full MCD Calculator →
📬

Get this MEDXF vs MCD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MEDXF vs SCHDMEDXF vs JEPIMEDXF vs OMEDXF vs KOMEDXF vs MAINMEDXF vs YUMMEDXF vs QSRMEDXF vs SBUX

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.